Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.180 -0.060 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer. 
Via Benzinga
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Where Will Iovance Biotherapeutics Be in 5 Years?
Via The Motley Fool
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Via The Motley Fool
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
A handful of bullish factors are converging at the right time in the right way for all three of these companies. 
Via The Motley Fool
Prediction: This Stock Will Beat the Market in 2025
Via The Motley Fool
Peering Into Iovance Biotherapeutics's Recent Short Interest
 
Via Benzinga
Is Iovance Biotherapeutics Stock a Millionaire Maker?
Via The Motley Fool
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
My 3 Favorite Stocks to Buy Right Now
The market's underestimating how well each of these companies should be able to capitalize on their opportunities. 
Via The Motley Fool
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
What's Wrong With Iovance Biotherapeutics Stock?
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Shares Are Falling Today: What's Going On?
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are trading lower Friday. The company announced the inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). 
Via Benzinga
3 Mid-Cap Stocks That Could Take Off in 2025
Via The Motley Fool
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
Via The Motley Fool
A Peek at Iovance Biotherapeutics's Future Earnings
 
Via Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
These windows of opportunity aren't likely to remain open for much longer. 
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
Just be ready to ride out some inevitable turbulence along the way. 
Via The Motley Fool
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
2 Innovative Stocks That Could Deliver Outsize Returns
Via The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.